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Abstract
Background: Diabetic nephropathy is a serious complication of diabetes mellitus and is associated with
considerable morbidity and high mortality. There is increasing evidence to suggest that dysregulation of the
epigenome is involved in diabetic nephropathy. We assessed whether epigenetic modification of DNA methylation
is associated with diabetic nephropathy in a case-control study of 192 Irish patients with type 1 diabetes mellitus
(T1D). Cases had T1D and nephropathy whereas controls had T1D but no evidence of renal disease.
Methods: We performed DNA methylation profiling in bisulphite converted DNA from cases and controls using
the recently developed Illumina Infinium® HumanMethylation27 BeadChip, that enables the direct investigation of
27,578 individual cytosines at CpG loci throughout the genome, which are focused on the promoter regions of
14,495 genes.
Results: Singular Value Decomposition (SVD) analysis indicated that significant components of DNA methylation
variation correlated with patient age, time to onset of diabetic nephropathy, and sex. Adjusting for confounding
factors using multivariate Cox-regression analyses, and with a false discovery rate (FDR) of 0.05, we observed 19
CpG sites that demonstrated correlations with time to development of diabetic nephropathy. Of note, this included
one CpG site located 18 bp upstream of the transcription start site of UNC13B, a gene in which the first intronic
SNP rs13293564 has recently been reported to be associated with diabetic nephropathy.
Conclusion: This high throughput platform was able to successfully interrogate the methylation state of individual
cytosines and identified 19 prospective CpG sites associated with risk of diabetic nephropathy. These differences in
DNA methylation are worthy of further follow-up in replication studies using larger cohorts of diabetic patients
with and without nephropathy.
Background
Diabetic nephropathy is a serious microvascular compli-
cation of diabetes and has become the most common
cause of end-stage renal disease (ESRD) in many national
ESRD registries [1,2]. Approximately one third of diabetic
individuals will develop clinically apparent nephropathy
characterised by persistent proteinuria, hypertension and
eventual progressive decline in glomerular filtration rate
[3,4]. Whilst chronic hyperglycaemia is integral to the
pathogenesis of diabetic nephropathy there is also strong
evidence for a genetic susceptibility to this common
complication of diabetes [5-7]. In genetically susceptible
individuals, prolonged hyperglycaemia leads to chronic
metabolic and haemodynamic changes [8,9] whose
effects, including those driven by transforming growth
factor beta 1 (TGFb1), promote structural abnormalities
in the kidney such as glomerular basement membrane
thickening, podocyte injury, and mesangial matrix expan-
sion, with the later development of irreversible glomeru-
lar sclerosis and tubulointerstitial fibrosis [10].
Genetic studies have found evidence for linkage to
nephropathy at a number of chromosome loci including
2q, 3q22 and 19q [11,12]. While no consistently repli-
cated genetic associations have been identified, various
candidate gene associations in diabetic nephropathy in
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type 1 diabetes (T1D) have been proposed, such as the
SNP rs13293564 G/T substitution in intron 1 of
UNC13B [13], and SOD1 SNPs [14]. An association
with the ELMO1 gene and diabetic nephropathy was
initially identified in patients with type 2 diabetes melli-
tus [15] and this association has now also been reported
for diabetic nephropathy in T1D [16]. A recent genome-
wide association study identified FRMD3 and CARS
gene variants as possible genetic susceptibility factors
for T1D diabetic nephropathy [17].
Epigenetic mechanisms allow alteration of genome
function without mutating the underlying sequence.
They involve the interacting actions of DNA methyla-
tion (the addition of a methyl group to the 5th carbon
position of cytosine), histone modifications and non-
coding RNAs [18]. A number of indirect lines of evi-
dence point to the involvement of epigenetic changes in
diabetic nephropathy. Murine models of disease progres-
sion displaying temporal variation in gene expression
have indicated these supra-sequence devices may be
involved in the pathogenesis [19]. Gene expression
changes reflect dynamic alterations in gene transcription
and also messenger RNA stability, which may be influ-
enced by the epigenetic modification of the genome in
response to chronic hyperglycaemic stress. Altered DNA
methylation has been additionally implicated in vascular
disease [20,21]. Furthermore, characteristics observed in
diabetic nephropathy such as hyperhomocysteinaemia,
dyslipidaemia, inflammation and oxidative stress can
promote aberrant DNA methylation [22-24].
DNA methylation in mammalian species, except for
pluripotent stem cells [25,26], appears to occur almost
exclusively at consecutive CpG dinucleotides, of which
there are approximately 28 million located within the
human genome [27]. The majority of cytosines in these
dinucleotides remain methylated (~80% in Homo
sapiens) [27], which contrasts with CpG islands (CGIs)
in which cytosines are generally unmethylated. CGIs are
regions that exceed genome average levels of CpG den-
sity and co-localise with 72% of gene promoters [28],
notably in those of highly expressed genes.
In order to assess possible changes in CpG methylation
in a genome-wide manner we utilised the high throughput
Illumina Infinium® Human Methylation27 BeadChip DNA
methylation array to investigate association with nephro-
pathy in a case-control study of 192 T1D patients. These
probes interrogate the methylation state of 27,578 indivi-
dual CpGs located predominately in CGIs within proximal
promoter regions, between 1.5 kb upstream and 1 kb
downstream of the transcription start sites of 14,475 con-
sensus coding sequence genes throughout the genome.
Furthermore 110 miRNA promoters are targeted with 254
CpG loci probes [29]. This platform enables the high-
throughput array based investigation of individual CpGs at
a magnitude higher level than the previous array based
Golden-Gate assay [30].
The development, as well as the progression, of diabetic
nephropathy has been linked to the same inflammatory
cell processes that are implicated in the progression of
T1D itself, such as the activated T cells involved in the
destruction of islet b cells [7]. Thus changes in the
expression of cytokines and other inflammatory markers
from distinct blood cell types make the investigation of
methylation changes in DNA derived from blood a plau-
sible option for examining epigenetic alterations in this
disease. DNA methylation changes in peripheral blood
have additionally been shown to indicate or be surrogate
markers of active disease processes [31].
This study has investigated the possibility to identify
DNA methylation biomarkers in peripheral blood cell-
derived DNA that may be associated with the pathogen-
esis of T1D nephropathy. The study was designed to
detect associations between the disease and differences
in DNA methylation but not their functional relation-
ship. Undertaken in a case control design, those with
and without nephropathy were matched by age of onset
and duration of diabetes.
Methods
Participants
Cases (n = 96) and controls (n = 96) were recruited
from nephrology and diabetic clinics in Belfast and
Dublin (Table 1). Genomic DNA was extracted from
whole blood samples from cases and controls using a
salting out method. All participants were white, with
parents and grandparents born in Northern Ireland or
the Republic of Ireland. Both cases and controls were
diagnosed with T1D before the age of 31 years and
required insulin from time of diagnosis. The definition
of a case was based on development of persistent protei-
nuria (> 0.5 g protein/24 h) at least 10 years after diag-
nosis of diabetes, hypertension (BP > 135/85 mmHg or
treatment with antihypertensive agents) and presence of
diabetic retinopathy. In contrast, a control was defined
as a patient with T1D duration of at least 15 years with
urinary albumin excretion in the normal range and not
receiving antihypertensive treatment. Patients with
Table 1 Subjects
Controls Cases
Number 96 96
Age 43.2 42.8
Sex (M/F) 47/49 48/48
Age at Diagnosis 16.3 16.2
Duration T1D 27.8 27.5
Subjects: Number, Average Age, Sex proportion (Male/Female), Duration of
T1D
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microalbuminuria were excluded from both groups.
Cases and controls were matched for confounders that
may affect DNA methylation namely age, gender and
duration of diabetes within five year windows. Study
approval for each recruitment site was obtained from
respective research ethics committees (Queens Univer-
sity Belfast and Mater Misericordiae Hospital, Dublin)
and written informed consent was obtained from all
participants.
Bisulphite conversion of DNA
Bisulphite conversion of 1 ug genomic DNA was per-
formed using the EZ-96 DNA Methylation-Gold™ Kit
(©Zymo Research Corp., USA) in two 96 well plates
according to the manufacturer’s instructions. Cases and
controls were randomly located between the two plates.
Effective bisulphite conversion was checked by success-
ful PCR amplification with a pair of primers specific for
converted DNA and unsuccessful amplification with a
pair of primers for unconverted DNA, of 24 random
samples across both plates (details available on request
from authors).
Illumina Infinium methylation assay
DNA samples from cases and controls were interrogated
utilising the Illumina Infinium® Human Methylation27
BeadChip. This platform detects the methylation status
of 27,578 CpG sites by sequencing-based genotyping of
bisulphite treated DNA. The chromosomal distribution
and other statistics relevant to these CpG sites are pro-
vided in Additional File 1: Supplementary Figure S1. This
chemical modification of DNA converts only unmethy-
lated cytosines to uracils, thereafter allowing for highly
multiplexed genotyping with single site resolution. Bisul-
phite converted and unconverted (i.e. methylated) sites
are simultaneously evaluated by hybridisation of DNA to
site-specific probes attached to beads, one for unmethy-
lated and the other for methylated sites, followed by allele
specific base extension that includes a fluorescent label.
Two different labels are used, and fluorescent signals are
specific for either the T (unmethylated) or C (methy-
lated) alleles. Methylation scores represented as b values
are generated for each site using BeadStudio 3.2 software
(©Illumina, Inc. 2003-2008) and are computed based on
the ratio of methylated to methylated plus unmethylated
signal outputs. Thus the b values range from 0 (unmethy-
lated) to 1 (fully methylated) on a continuous scale.
This platform for quantitative methylation, essentially
an adaptation of the highly successful Illumina Infinium
I Whole Genome Genotype SNP genotyping assay used
extensively for GWAS [32,33], is extremely accurate and
powerful. Reproducibility estimates are extremely high
with an average r2 correlation for b-values of 0.992 for
24 technical replicates [29]. Due to the high density of
probes up to 12 separate samples can be assayed on a
single BeadChip, thus allowing for high-throughput
processing.
The Illumina Infinium methylation assay was per-
formed according to the manufacturer’s instructions, and
this along with the technical validation of the assay is
detailed in Bibikova et al. [29]. Bisulphite-converted
DNA was denatured, amplified, fragmented and subse-
quently hybridised, with use of a specific hybridisation
buffer, to the chip arrays (Sentrix positions A-L). Cases
and controls were arranged to randomly approximate a
50:50 proportion on each chip. Primer extension was per-
formed, then staining and coating, followed by imaging
with the Illumina BeadArray reader. Internal quality con-
trols included assessment of staining, hybridisation, tar-
get removal, extension, bisulphite conversion efficiency,
dye specificity and additionally negative controls.
Statistical analysis
Initial array results were visualised using Illumina® Bead-
Studio 3.2 (© Illumina Inc 2003-2008). All computations
and statistical analyses were performed using the R
package (R 2.8.1) (http://www.r-project.org) [34] and
Bioconductor [35].
Quality control and data normalisation
Quality control and normalisation of methylation data
was undertaken using the analysis pipeline reported else-
where [31]. Briefly, samples were monitored for coverage
(fraction of CpGs with detectable intensity values above
background) and bisulphite conversion efficiency (BSCE)
using the controls provided on the Illumina Beadchip. Of
the 192 samples, one sample had failed BSCE and an
additional four samples had relatively low coverage and
BSCE. These samples were removed, leaving a total of
187 samples with approximately 81% global coverage
(22,486 CpG sites). Intra-array normalisation was per-
formed by the Illumina BeadStudio 3.2. software. The
resulting b-valued data matrix was normalised further
using a quantile-normalisation strategy, designed to
reduce unwanted inter-array variation. The normalised
and raw data are available from GEO (Gene Expression
Omnibus, NCBI) under the accession number GSE20067.
Singular Value Decomposition and Significance of Singular
Values
Singular Value Decomposition (SVD) provides a linear
representation of the data in terms of a relatively small
number of components, which capture the most salient
patterns of variation [36]. We verified that the first com-
ponent of a SVD analysis on the b-valued data matrix
captures over 90% of the variation in the data, repre-
senting the inherent bi-modality of the methylation
value distribution (see Figures 1a and 1b). Thus, to cor-
rectly evaluate the statistical significance of the remain-
ing components of variation, the normalised data matrix
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needs to be adjusted by removing this background varia-
tion, by subtracting out the top principal component.
This is essentially equivalent to normalising the data
matrix by the mean profile. SVD was subsequently reap-
plied to the normalised adjusted data and the spectrum
of singular values compared to the null distribution
obtained by considering random matrices [37,38]. Speci-
fically, the normalised adjusted data was randomised by
permuting the CpGs, using a distinct permutation for
each sample. Subsequently, SVD was performed on the
randomised data matrix and the fraction of variation of
the inferred singular values compared to the fractions of
variation of the unpermuted data (Figure 2). Using mul-
tiple randomisations we verified that the null distribu-
tion of singular values was very tight (Figure 2), as
expected since null singular values reflect a global prop-
erty of the randomised data, which should be robust to
further randomisations of the data. Thus, significant
components of variation were selected as those whose
variation was larger than the expected variation under
the null-hypothesis. This gave five principal components
in addition to the top component, making a total of six.
The biological significance of the five components of
variation (top principal component did not correlate
with any phenotype) was tested by correlation to pheno-
types of interest and experimental factors (Figure 3).
For continuous and ordinal variables (e.g. BSCE, age)
associations were evaluated using linear regression, for
categorical variables (e.g. Beadchip) we used a Kruskal-
Wallis test. For the time to onset of nephropathy
Figure 1 Average b values. Figure 1a (top): Controls, Figure 1b (bottom): Cases - Average b values across array.
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(CC-case/control) we used a Cox-regression with time
to event = time to onset of nephropathy (NP), and event =
1 (NP), 0 (no NP).
Supervised analysis
Association between CpG-valued methylation profiles
and diabetic nephropathy was performed using a Cox-
regression model where time to event equals the time
between diagnosis of T1D to the onset of nephropathy.
Multivariate regressions were performed for each CpG
separately and included factors for chip, BSCE, sex,
cohort and age at sample draw. To correct for multiple
testing we estimated the false discovery rate (FDR) using
the q-value framework [39]. We have shown previously
that the analytical q-value estimates are similar to those
obtained using permutations of sample labels preserving
the potential correlative structure between CpGs [31].
Results
Methylation profile of arrays
The methylation values as defined by b scores ranging
between 1 and 0, or fully to non-methylated, are dis-
played for all 27,578 CpGs queried as histograms in Fig-
ures 1a and 1b, for controls and cases respectively. Both
show a similar pattern with a high peak of hypomethy-
lated loci and a low peak in the hypermethylated loci.
This is the expected U shape of methylation pattern of
the genome but due to the array design which is skewed
towards promoter region CpGs in CGIs shows the
reverse pattern with a larger peak at the low end of the
distribution. The minimum and maximum b values
results for a representative chromosome, chromosome
1, are shown in Figure 4. This displays the individual
results for the 2,903 probed CpGs that reside across this
chromosome, for cases and controls separately. Scatter
plots showed highly equivalent intensity scores
(r2 = 0.9990) and average b scores (r2 = 0.9996) between
cases and controls (data not shown).
DNA methylation analysis
SVD of the normalised data revealed significant compo-
nents of variation that correlated with age, time to onset
of nephropathy, sex, but also with experimental factors
including chip, cohort and bisulphite conversion effi-
ciency (Figures 2 and 3). As age and experimental fac-
tors could confound the analysis, we identified CpGs
correlating with time to onset of nephropathy by apply-
ing a multivariate Cox-regression model to each CpG
site, including the confounding factors as covariates. We
observed that the resulting p-value distribution was
Figure 2 Fraction of variation associated with principal
components. Fraction of variation associated with principal
components after adjustment for the top component which
captures the inherent bi-modality of the methylation distribution.
Red denotes the observed values, black denotes those obtained by
randomly scrambling up the data matrix. Each black dot represents
the value of 10 distinct randomisations, which all yield the same
value as singular values represent measures of global variation
which themselves are invariant under a global randomisation of the
data.
Figure 3 Correlation of principle components to phenotype/
experimental factors. Correlation of principal components (top
component removed as it did not correlate with any phenotype) to
phenotypes of interest and experimental factors: BS conversion
(bisulphite conversion, C1(green), C2(blue)), Sex, Cohort, Chip, Batch,
Age at Draw (Age when sample taken), Duration T1D, Age at
Diagnosis, CC (time to onset of NP) Colour key: dark red = p value
< 10-10, red = p value < 10-5, orange = p value < 10-2, pink = p
value < 0.05, white = p value > 0.05.
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significantly different from a uniform distribution with
an excess of p-values close to 0, suggesting that a signif-
icant number of CpGs are correlated with time to onset
of nephropathy (Figure 5). This involves the contribu-
tion of directional methylation increases or decreases
observed in cases, with respect to the period of time
that nephropathy took to develop, and controls, whom
had had a variable period of T1D without developing
nephropathy. At an FDR = 0.15, we observed 263 CpGs
as conferring increased risk and 162 CpGs conferring
decreased risk for nephropathy, respectively (Additional
File 2: Supplementary Table S1). However, whether
these changes are related to cause or effect of early/late
onset of nephropathy cannot be answered by this study.
Gene set enrichment analysis searches for genes that
share common biological function, chromosomal
location, or regulation, and this analysis run on these
data using the Molecular Signatures Database (MSigDB
v2.5) [40] did not reveal any significant associations,
after correction for multiple testing. Using a more strin-
gent FDR of 0.05 resulted in a set of 19 CpGs and these
are listed in Table 2. The CpG cg07341907, located 5’ of
the UNC13B gene, was the only CpG near a previously
identified T1D nephropathy-associated candidate gene
within this group. The box plot for adjusted methylation
Z-score differences for this CpG is shown in Figure 6,
with higher levels of methylation in the case group
(0.00557) versus controls (-0.00563) (Uncorrected aver-
age b values were 0.147 and 0.157, for controls and
cases respectively). The putative association SNP
rs13293564 resides within the first intron of this gene
[13]. MUNC13, the protein coded for by UNC13B, has
Figure 4 Maximum and minimum b values for Chromosome 1. Maximum and minimum b values across the 2903 probed CpGs located on
Chromosome 1 for Controls and Cases.
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been shown to be up-regulated in the renal cortex of
rats with streptozotocin-induced diabetes and its expres-
sion is induced by hyperglycaemia [41].
To investigate whether there was a significant co-
directional change of CpGs within 1 kb of each other,
the normalised results for each of those proximal pairs
within this distance were combined and compared in a
case versus control analysis, with two of the genes in
Table 2, PPAPR3 (cg02590345 and cg16898420 - sepa-
rated by 119 bp) and TRPS1 (cg12569516 and
cg21312090 - separated by 534 bp) also being in the top
ten results of this analysis (data not shown).
Discussion
This study investigated the methylation state of approxi-
mately 14,000 CGIs in promoter regions of genes spread
throughout the genome in a cohort of 192 type 1 dia-
betic patients, half of whom had developed diabetic
nephropathy. A Cox-regression model was utilised
whereby the effect of a genetic susceptibility has a mul-
tiplicative effect over time on the risk of a subject devel-
oping nephropathy. This analysis, after accounting for
confounding effects, identified an excess of CpG sites
which were observed to have a change in methylation
status that could be correlated with duration of diabetes
prior to onset of nephropathy with a FDR of 0.15. Of
these observations 263 CpGs were identified as confer-
ring increased risk and 162 CpGs conferring decreased
risk for nephropathy, respectively and co-localised to
421 unique genic regions. However this dataset did not
reveal any significant enrichment of particular physiolo-
gical gene set pathways.
Using a more stringent FDR cut-off of 0.05, a set of 19
CpGs was identified (in 19 unique gene CGIs). One
CpG in this list, cg07341907 is located 18 bp upstream
of the transcription start site of a previously identified
type 1 diabetic nephropathy gene, UNC13B [13]. Levels
of methylation for this CpG were shown to be slightly
higher in the case group compared with controls. Whilst
expression of this gene has been shown to be increased
in models of nephropathy and hyperglycaemia [41] the
expression effect of methylation changes can often be
difficult to predict [42]. The other CpG assayed within
this genic region, cg02096633, is located ~0.5 kb further
downstream, 197 bp into the first intron and shows con-
sistently low methylation levels in both cases and con-
trols (b-value averages 0.051 and 0.052 respectively).
The susceptibility SNP, rs13293564 resides within the
first intron and in Caucasians (from CEU HapMap data)
is within a linkage disequilibrium block of 23 kb that
includes the CGI. Tregouet et al. could determine no
plausible function for the intronic SNP, however did
identify five SNPs in strong linkage disequilibrium with
this SNP that reside within the plausible promoter
region [13]. Two of which (rs10081672 and rs10972333)
were found to affect potential transcription factor bind-
ing sites. Additionally, the former SNP (rs10081672) cre-
ates or abrogates a CpG site depending on which allele
is present. Therefore, modification of the promoter
region of this gene whether genetically or epigenetically
or in combination could influence its expression by
affecting transcription factor binding. Tregouet et al.
proposed that UNC13B mediates apoptosis in glomeru-
lar cells due to hyperglycemia, and they therefore sug-
gested that this association could indicate initiation of
nephropathy [13].
Whilst the 27K Infinium assay enables high-through-
put investigation of individual CpG sites with high reso-
lution, and is a considerable improvement on the
previous Golden-Gate methylation assay, this methodol-
ogy still has some limitations. Only approximately 0.1%
of the total number of CpGs within the genome are
assessed, however the placement of these CpGs are pre-
dominately within the CpG Islands with high likelihood
of critical effects on promoter activity. As these CpGs
can significantly affect or silence expression, changes
can be more deleterious than gene sequence variants,
therefore increasing the potential power of the assay.
Additionally not all CpG sites need to be assessed as
correlation of CpG status between sites can extend up
to 1 kb [43]. Whist dramatic switching on or off facili-
tated by DNA methylation may occur within these pro-
moter regions, more subtle and perhaps dynamic effects
Figure 5 Nephropathy and duration type 1 diabetes p values.
Histogram of p-values after explicit correction for all potentially
confounding factors reveals an excess of significant p values for
CpGs correlated with Nephropathy and duration of Type 1 Diabetes.
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may however be missed that are occurring in the sur-
rounding CGI shores (regions within 2 kb of the islands)
[44]. Changes in gene body methylation that may influ-
ence the expression of certain isoforms, by effecting the
inclusion or exclusion of certain exons, are also not
assayed. Additionally this array does have a bias towards
cancer and imprinted genes; with ~200 of these having
3-20 CpG probes per promoter. Increasing knowledge
with regards to the most biologically informative CpG
sites and future up scaling will undoubtedly improve
targeted platforms, although a more in depth investiga-
tion of all of the CpGs of the genome would require a
differing approach. An enrichment technique such as
MeDIP-Seq would gain a representative genome wide
picture but this lacks the base pair resolution of this
array [45]. Isolated studies utilising full bisulphite
sequencing of a very small number of genomes have
recently been published [26], however scaling up to
large numbers of cases and controls currently remains
prohibitive due to cost.
Like all genome-wide association studies this study was
designed to find statistically significant associations, in
this case with DNA methylation variation not with geno-
type, but not to identify the underlying mechanism(s) for
the cause or function of the observed variation. Although
DNA methylation is tissue-specific, examination of
Table 2 Methylation Associations
Ilmn CpG
ID
Gene Gene Function Location coef exp
(coef)
se
(coef)
z Pr(> |z|) Q
value
cg01172656 NRBF2 Transcription regulation 10:64563126 0.631 1.880 0.136 4.653 3.266 × 10-
06
0.031
cg18346038 PIGU GPI-anchor biosynthesis 20:32728489 0.624 1.867 0.136 4.603 4.164 × 10-
06
0.031
cg00117172 RUNX3 Transcription regulation 1:25128425 0.682 1.977 0.150 4.548 5.427 × 10-
06
0.031
cg02068676 COBRA1 Negative regulation of transcription 9:139269304 0.662 1.938 0.149 4.447 8.703 × 10-
06
0.037
cg00025138 MAP3K9 Mixed-lineage kinase 14:70345670 0.543 1.721 0.125 4.335 1.457 × 10-
05
0.046
cg03221776 MFSD3 Transmembrane transport 8:145704779 0.520 1.682 0.121 4.308 1.644 × 10-
05
0.046
cg12181621 HIST1H3I Nucleosome assembly 6:27948047 0.558 1.748 0.132 4.216 2.486 × 10-
05
0.048
cg03752885 DAPK3 Induction of apoptosis 19:3920736 0.492 1.636 0.118 4.189 2.798 × 10-
05
0.048
cg12688215 KTI12 ATP binding 1:52271816 0.446 1.563 0.107 4.175 2.976 × 10-
05
0.048
cg07341907 UNC13B Exocytosis 9:35151971 0.606 1.833 0.145 4.169 3.056 × 10-
05
0.048
cg26850145 ZBTB5 Transcription regulation 9:37455023 -0.485 0.616 0.117 -4.142 3.441 × 10-
05
0.048
cg21312090 TRPS1 NLS-bearing substrate import into nucleus 8:116750901 0.441 1.555 0.107 4.135 3.543 × 10-
05
0.048
cg23266266 DCUN1D4 - 4:52403466 0.560 1.751 0.136 4.117 3.847 × 10-
05
0.048
cg04466870 SFXN4 Transmembrane transport 10:120915170 0.477 1.611 0.116 4.102 4.092 × 10-
05
0.048
cg16898420 PPAPR3 Catalytic activity 9:102830899 -0.711 0.491 0.175 -4.066 4.786 × 10-
05
0.048
cg17260725 CCNB2 Cell division 15:57184580 0.523 1.687 0.129 4.0596 4.915 × 10-
05
0.048
cg17428423 DOC2A Regulation of calcium ion-dependent
exocytosis
16:29929633 -0.728 0.483 0.180 -4.053 5.049 × 10-
05
0.048
cg18731014 ZNF639 Transcription regulation 3:180524284 0.556 1.744 0.137 4.050 5.122 × 10-
05
0.048
cg21830413 VPS26 Protein transport 10:70554257 0.472 1.604 0.117 4.036 5.430 × 10-
05
0.048
Cox-Regression analysis results of CpGs, with FDR (q value) < 0.05, for time to develop nephropathy. (Location given as Chromosome:Base Pair (Build Hs 36.1))
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peripheral whole blood was informative in this case in
order to determine whether any genome-wide methyla-
tion signal changes could be detected in this easily acces-
sible surrogate tissue. Whilst only a small number of
significant sites were identified, due to the stringent
False Discovery Rate cut-off implemented, this experi-
ment did identify possible biomarkers in this pathogenic
process with more easily implementable clinical utility
potential. Therefore, this indicates that active disease
processes can be identified in the DNA methylation
pattern of peripheral blood and be a possible marker of
these [31]. The development, as well as the progression,
of diabetic nephropathy has been linked to the same
inflammatory cell changes that are implicated in the pro-
gression of T1D itself, such as the activated T cells
involved in the destruction of islet b cells [7]. Further-
more, additional inflammatory-related or other signals
may be present in peripheral blood DNA that require
isolation of specific cell types to detect and other methy-
lation change signals may only be able to be identified in
the affected renal cells themselves.
Conclusion
This study is one of the first to investigate a complex
disease trait utilising this high-throughput DNA methy-
lation 27 K array based assay. The effect of length of
T1D status before developing or not developing nephro-
pathy was observed to show a correlation with respect
to methylation scores of individual CpG loci. By the
examination of a cohort of 192 T1D patients this study
has confirmed the utility of this approach to genome
wide DNA methylation analysis and the potential pro-
spects for larger and subsequent replication studies of
epigenomic factors in common diseases.
Additional material
Additional file 1: Supplementary Figure S1. Distribution of CpG sites
on Infinium platform. (Top, Left) Chromosome Distribution of CpG sites.
(Top, Right) Distance to Transcription Start Site of CpG Locus. (Bottom,
Left) Interrogated CpG Islands: near genes, near miRNA. (Bottom, Right)
Number of CpG sites per CpG Island.
Additional file 2: Supplementary Table S1. List of CpGs with q value <
0.15. Column headings are IlmnID = Illumina CpG ID, Gene_ID = Entrez
Gene ID, Symbol = Gene Symbol, coef = coefficient, exp(coef) =
exponential of coefficient, se(coef) = standard error of coefficient, z = z
score, Pr(> |z|) = probability greater than absolute z score, q value
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